Thursday October 22, 2020

Elan enters new agreement on potential Alzheimer's agent

Irish headquartered biotechnology firm Elan has entered into a manufacturing agreement for the supply of an active pharmaceutical ingredient with Lonza Group to advance its work on Alzheimer’s Disease.

30th November, 2011
2
{ }

Irish headquartered biotechnology firm Elan has entered into a manufacturing agreement for the supply of an active pharmaceutical ingredient with Lonza Group to advance its work on Alzheimer’s Disease.

The new agreement on the ingredient, ELND005, is “fundamental to ensuring that a high quality supply of ELND005 will be available to support the advancement of the program,” said a statement from Elan.

.A recent conference highlighted the role ELND005 could have...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 9 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 5 years ago